Stocktoria
Nasus Pharma Ltd NSRX
Nasus Pharma Ltd (NSRX) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $1.2B at a -0.5% net margin.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 2036 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.538 |
| Retained earnings / assets | -3.701 |
| EBIT / assets | -0.98 |
| Equity / liabilities | 1.238 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| NSRX | Nasus Pharma Ltd | 3/9 | -13.82 | — | — |
| INDV | Indivior Pharmaceuticals, Inc. | 4/9 | -0.7 | 24.3 | +4.3% |
| PBH | Prestige Consumer Healthcare Inc. | 5/9 | 4.04 | 12.3 | -4.3% |
| ACAD | ACADIA PHARMACEUTICALS INC | 4/9 | 3.79 | 11.1 | +11.9% |
| ALKS | Alkermes plc. | 5/9 | 6.24 | 38 | -5.2% |
| MDGL | MADRIGAL PHARMACEUTICALS, INC. | 3/9 | -1.18 | — | +432.1% |
| PAHC | PHIBRO ANIMAL HEALTH CORP | 6/9 | 4.7 | 12.9 | +17.1% |
About Nasus Pharma Ltd
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.
FAQ
Is NSRX financially healthy?
Nasus Pharma Ltd's Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does NSRX pay a dividend?
No, Nasus Pharma Ltd does not currently pay a dividend.
How profitable is NSRX?
In FY2025, Nasus Pharma Ltd had a net margin of -0.5% and a return on equity of -211.6%.
What is the analyst price target for NSRX?
The average Wall-Street price target for Nasus Pharma Ltd is $19.67, about 465.1% above the recent price, from 3 analysts (consensus: buy).
Is NSRX a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Nasus Pharma Ltd: a Piotroski F-score of 3/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.